BioRestorative Therapies Announces FDA Clearance of Phase 2 BRTX-100 Clinical Study Protocol Amendment
Posted on Tuesday April 16, 2024

— Amendment replaces saline injections with sham injections in the control group — MELVILLE, N.Y., April 16, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has cleared an important amendment to the protocol of the ongoing Phase 2 study investigating the use of BRTX-100, the Company’s lead cell therapy

10 Micro-Cap Healthcare Stocks Insiders Are Buying
Posted on Sunday April 14, 2024

In this article, we will take a detailed look at the 10 Micro-Cap Healthcare Stocks Insiders Are Buying. For a quick overview of such stocks, read our article 5 Micro-Cap Healthcare Stocks Insiders Are Buying. Investors have always been interested in the connection between insider buying and stock returns. Over the past several years there’s been a huge influx […]

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease
Posted on Monday April 08, 2024

— Collaboration follows recent manufacturing/clinical process enhancements that have tripled monthly trial capacity — — Patient enrollment expected to be completed in 2024 — MELVILLE, N.Y., April 08, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced a collaboration with Galen Patient Recruitment, Inc. (“Galen”) which, combined with the recent expansion o

BioRestorative Therapies Announces Filing of Form S-1 Registration Statement to Register for Resale Common Stock Underlying Previously Issued Warrants
Posted on Wednesday April 03, 2024

- Company is not offering shares pursuant to the registration statement - MELVILLE, N.Y., April 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced the filing of a registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”). The registration statement solely covers the resale by selling securityholders of up to 2,513,686